Fritextsökning
Innehållstyper
-
Recipharm divests five Swedish plants
Swedish contract manufacturer Recipharm is selling its facilities in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development to US private equity compa...
-
ProPharma
-
Don't miss out on this unique opportunity
ZEISS QUALITY INNOVATION SUMMIT October 22 - 24 in Berlin.
-
ZEISS Metrology Shop provides planning security
ZEISS Metrology Shop brings it all together.
-
Obesity-drug pioneers win Lasker Award
This year’s Lasker Prize in Clinical Research has been awarded to three researchers for their discoveries in GLP-1-based drugs that, according to the jury, “hav...
-
Advancing 3D Culture Imaging: Insights from Academia, Biotech, and Pharma
Webinar | March 13, 2024, 12 PM EST.
-
Clean solutions - Handling viscose substances with precision
Paar, is one such solution – and uses electric axes and control systems from Festo.
-
SMC Corporation Appoints Bianca Brunell as New General Manager for the Nordic and Baltic Countries
SMC Corporation is pleased to announce the appointment of Bianca Brunell as the new General Manager for SMC’s Nordic and Baltic countries, effective June 1, 2024.
-
Nocebo – the evil twin that makes you feel worse
The placebo effect is well known in healthcare, but not so its opposite: nocebo. “The effect is small, but it can have major repercussions,” says Uppsala resear...
-
High-performance Slide Scanner for Fluorescence, Brightfield and Polarization
ZEISS Axioscan 7 combines high speed digitization and outstanding image quality.
-
EU Pharmaceutical Legislation Reform
The EU's Pharmaceutical Legislation Reform, proposed by the commission within the European Health Union, aims to establish a citizen-centric framework to enhanc...
-
A new giant among our microscopes
Two technologies in one machine.
-
Beta-blockers are often given unnecessarily, a study finds – “This will affect future practice”
Patients who have suffered a minor heart attack do not benefit from beta-blockers, according to a major new study that may change guidelines for cardiac care.
-
Forskaren in Hagastaden now inagurated
The real estate company Vectura's life science center in Hagastaden, Forskaren, is now inaugurated. The opening was attended by people from the industry, politi...
-
The dock that “thinks” for itself
The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...
-
Eli Lilly to build a USD 2.5-billion plant in Germany
US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.
-
An increasing number of people are falling ill with TBE – “Much more research is needed”
Tick-borne meningitis, or TBE, is an increasingly common disease in Sweden. Currently, there is a vaccine against the disease but no drugs. Researcher Anna Över...
-
Positivt USA-besked om Alzecures smärtpreparat
Alzecure har beviljats särläkemedelsstatus i USA för smärtpreparatet ACD440.
-
Venom from the deathstalker carries radiopharmaceuticals to the brain
In order to target cancerous brain tumours with radionuclides, the problematic blood-brain barrier must first be crossed. Life Science Sweden has visited a KI r...
-
"Unclear proposal from the EU Commission on how to solve the MDR challenges"
Even before the EU regulation on medical devices (MDR) came into force, medical technology companies and doctors were concerned that it would endanger the avail...
-
Specific proposals and targets top the universities’ desired priorities
What are the universities’ expectations for the update of the national life science strategy? Life Science Sweden posed the question to representatives from Kar...
-
Zelmic
-
Leo Pharma to cut 200 jobs and reorganize
Danish Leo Pharma cuts down on staff in its global operations. Around 200 positions will be cut, while 50 will be moved to Poland.
-
Anna Törner: The clinical trial – Periscope to reality
What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.